Systolic versus diastolic blood pressure and risk of coronary heart disease: The Framingham study

doi:10.1016/0002-9149(71)90428-0

The American Journal of Cardiology

Volume 27, Issue 4, April 1971, Pages 335-346

https://doi.org/10.1016/0002-9149(71)90428-0 Get rights and content

Abstract

A comparison of the contribution of systolic versus diastolic blood pressure to risk of coronary heart disease and the role of mean arterial pulse pressure and systolic lability have been examined prospectively in 5,127 men and women during 14 years of biennial follow-up studies.

Similar gradients of risk of subsequent coronary heart disease were observed whether persons were classified by their systolic or diastolic pressure, and no “safe” or critical level could be identified. Assessment of the net effect of each, employing discriminant analysis, indicated a stronger association of systolic than diastolic pressure with risk of coronary heart disease. Neither the systolic and diastolic pressure measurements in combination nor the pulse pressure and the mean arterial pressure measurements alone discriminated better than the systolic measurement alone. Systolic lability did not predict incidence of coronary heart disease independently of the associated level of blood pressure.

There was a trend of declining relative importance of diastolic and a corresponding increase in the importance of systolic pressure with advancing age. Only in those under 45 was diastolic pressure predominant. The level of casually obtained blood pressure was a good predictor of coronary heart disease. The current practice of assessing the importance of blood pressure at all ages largely on the basis of diastolic pressure and the commonly held view concerning the innocuous nature of an elevated level of systolic pressure in the elderly requires reevaluation.

References (27)

JN Morris et al.
Incidence and prediction of ischemic heart disease in London busmen
Lancet
(1966)
T Gordon et al.
Some methodologic problems in the long-term study of cardiovascular disease: observations on the Framingham study
J Chronic Dis
(1959)
S Weiss et al.
Quantitative aspects and dynamics of circulatory mechanism in arterial hypertension
Amer Heart J
(1930)
RS Gubner
Systolic hypertension: a pathogenetic entity. Significance and therapeutic considerations
Amer J Cardiol
(1962)
WB Kannel et al.
The coronary profile: 12 year follow-up in the Framingham study
J Occup Med
(1967)
O Paul et al.
A longitudinal study of coronary heart disease
Circulation
(1963)
JT Doyle et al.
Early diagnosis of ischemic heart disease
New Eng J Med
(1959)
WB Kannel et al.
Vascular disease of the brain. Epidemiologic aspects: the Framingham study
Amer J Public Health
(1965)
TR Dawber et al.
An approach to longitudinal studies in a community: the Framingham study
Ann NY Acad Sci
(1963)
GD Friedman et al.
An evaluation of follow-up methods in the Framingham heart study
Amer J Public Health
(1967)

CK Friedberg

Diseases of the Heart

TR Harrison

Principles of Internal Medicine

PB Beeson et al.

Cited by (752)

General Population and Global Cardiovascular Risk Prediction
2023, Hypertension: A Companion to Braunwald's Heart Disease
Hypertension afflicts a substantial proportion of the adult population worldwide and a growing number of children. Numerous genetic, environmental, and behavioral factors influence the development of hypertension across the life course. In turn, hypertension has been identified as one of the significant causal risk factors for cardiovascular disease (CVD), including heart disease, peripheral vascular disease, stroke, and renal disease. Using the current definition of hypertension, data from recent United States National Health and Nutrition Examination Surveys (NHANES) from 2015 to 2018 indicate that the age-adjusted prevalence of hypertension among adults 20 years of age and older in the United States was 47.3%, or nearly one in two adults, with 51.7% of men and 42.8% of women affected. Among the entire population, approximately 121.5 million U.S. adults are estimated to have hypertension. When high-quality out-of-office modalities for measuring blood pressure are included, prevalence rates tend to be even higher. Prevalence rates increase dramatically with age, from 28.2% to 60.1% to 77.0% among those aged 20 to 39, 40 to 59, and 60 years or older, respectively. Trends in the prevalence of hypertension have tended to follow similar patterns in all racial/ethnic groups from the 1990s to the present. Despite significant advances in understanding the risk factors, pathogenesis, and sequelae of hypertension and multiple trials over the past five decades indicating the benefits of antihypertensive therapy, hypertension remains a significant public health problem. This chapter discusses these and many other related issues.
Nitric oxide deficiency is a primary driver of hypertension
2022, Biochemical Pharmacology
Hypertension remains a global health crisis. High blood pressure is the number one modifiable risk factor in the onset and progression of cardiovascular disease. Despite many different classes of drug therapies approved for hypertension, the use of polypharmacy and recommendations on lifestyle modification, many patients still suffer from uncontrolled or unmanaged hypertension. Nitric oxide is a naturally produced vasodilator that controls and regulates vascular tone and therefore controls and regulates blood pressure. Research over the past 40 years reveals that loss of nitric oxide production, termed endothelial dysfunction, is the earliest event in the development of hypertension. Strategies aimed at preventing the loss of nitric oxide production and/or therapeutic strategies designed to restore nitric oxide production will likely have a positive effect on patients’ health and lead to better management of blood pressure. This review article will focus on the loss of nitric oxide production as the primary contributor to hypertension and also discuss safe and clinically proven strategies to restore nitric oxide production and recapitulate nitric oxide based signaling in humans.
Impact of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed with premature ovarian insufficiency or an early menopause: a randomised pilot trial
2022, Maturitas
To compare the difference between micronised progesterone (MP) and medroxyprogesterone acetate (MPA) in combination with transdermal oestradiol (t-E₂) on cardiovascular disease (CVD) risk markers in women diagnosed with an early menopause and premature ovarian insufficiency (EMPOI).
The European Society for Cardiology has identified carotid femoral pulse wave velocity (cfPWV) as the gold standard cardiogenic biomarker for risk stratification of arterial disease. Menopause has been shown to augment the age-dependent increase in arterial stiffness, with hormone replacement therapy (HRT) being the mainstay of management of women diagnosed with EMPOI.
A pilot randomised prospective open-label trial. Women were randomised to either cyclical MP (Utrogestan® 200mg) or MPA (Provera® 10mg) in conjunction with t-E₂ (Evorel® Patches 50mcg/day) for 12 months. Seventy-one subjects were screened, and baseline data are available for 57 subjects.
Carotid-femoral pulse wave velocity (cfPWV).
PWV did not significantly change from baseline in either treatment arm. MP + t-E₂ demonstrated a positive effect on traditional CVD markers, with a significant improvement seen in cardiac output (CO) (0.71±1.01mL/min, 95% CI 0.20 to 1.21) and reduction in diastolic blood pressure (DBP) (-3.43±6.31mmHg, 95% Cl -6.57 to -0.29) and total peripheral resistance (TPR) (-0.15±0.19mmHg⋅min⋅mL⁻¹, 95% CI -0.24 to -0.05) after 12 months. MPA + t-E₂, in contrast, did not demonstrate significant changes from baseline in traditional haemodynamic parameters.
The positive changes in traditional markers were not reflected in the cardiogenic biomarker, cfPWV, which has demonstrated a higher positive predictive value for cardiovascular events than traditional measurements.
Application of bivariate meta-analytic approach for pooling effect measures of correlated multiple outcomes in medical research
2022, Clinical Epidemiology and Global Health
Citation Excerpt :
In medical research, we often measure more than one primary outcome variable to answer a single research question. Most often such variables are statistically correlated like systolic blood pressure and diastolic blood pressure (correlation coefficient, ‘r’ ranged from 0.68 to 0.83), triglyceride and high-density lipoprotein (HDL) (r = −0.46) or low-density lipoprotein (LDL) and Non HDL (r = 0.961).3–5 Dependency might arise between these variables either because the multiple outcomes are measured from the same set of individuals or the same outcome measured at multiple time points.
Multivariate meta-analysis is used when multiple correlated outcomes are reported in a systematic review. This study explored the application of multivariate meta-analysis in such a context. The objectives of the present study were to compare the summary findings and decisions between univariate and bivariate meta-analyses, as well as to assess how much sensitive the results are towards the strength of the correlation between the outcome variables.
A systematic review that reported two correlated outcomes, Intact parathyroid hormone levels and serum phosphate was chosen for demonstrating the applications of bivariate meta-analysis. Both univariate and bivariate meta-analyses with fixed effect and random effect models were carried out and the results were compared. A sensitivity analysis was performed for a wide spectrum of correlations from −1 to +1 to assess the impact of correlation on pooled effect estimates and its precision.
Pooled effect estimates generated through bivariate meta-analysis were found to be varying when compared to those obtained through univariate meta-analysis. The confidence interval of the pooled effect estimates obtained through bivariate meta-analysis was wider than in univariate meta-analysis. Further, the value of the pooled effect estimates along with its confidence intervals also differed for varied levels of correlations.
This study observed that when we have multiple correlated outcome variables to answer a single question bivariate meta-analysis could be a better approach. The magnitude of the correlation between the outcome variables also plays a vital role in meta-analysis.
Association of Dietary Approaches to Stop Hypertension diet and Mediterranean diet with blood pressure in less-developed ethnic minority regions
2022, Public Health Nutrition
Mixed effects logistic regression analysis of blood pressure among Ghanaians and associated risk factors
2023, Scientific Reports

View all citing articles on Scopus

View full text

Clinical studySystolic versus diastolic blood pressure and risk of coronary heart disease: The Framingham study

Abstract

Lancet

J Chronic Dis

Amer Heart J

Amer J Cardiol

The coronary profile: 12 year follow-up in the Framingham study

J Occup Med

A longitudinal study of coronary heart disease

Circulation

Early diagnosis of ischemic heart disease

New Eng J Med

Vascular disease of the brain. Epidemiologic aspects: the Framingham study

Amer J Public Health

An approach to longitudinal studies in a community: the Framingham study

Ann NY Acad Sci

An evaluation of follow-up methods in the Framingham heart study

Amer J Public Health

Diseases of the Heart

Principles of Internal Medicine

Clinical study
Systolic versus diastolic blood pressure and risk of coronary heart disease: The Framingham study